DNA Sequencing Market Trend to be Worth $21.30 Billion by 2031

The increasing prevalence of cancer is expected to boost the adoption of NGS in clinical settings. DNA sequencing is considerably contributing to researchers’ understanding of cancer biology. Genomics research supported by NGS has identified genetic heterogeneity even among cancer types that were earlier considered identical. The discovery of unique molecular signatures is helping in the development of potential cancer treatments, increasing the demand for NGS in cancer research.